FDA 483 - Boothwyn Pharmacy LLC - August 29, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
This FDA Form 483 details observations from an inspection of Boothwyn Pharmacy LLC, a producer of sterile and non-sterile drug products, located at 221 Gale Ln, Kennett Square, PA. The inspection was conducted from August 9 to August 29, 2023. Wayne C. Sartorio, Pharmacist-in-Charge, was the individual to whom the report was issued.
Five observations were noted:
1. **Inadequate Smoke Studies:** Unidirectional airflow was not verified under dynamic operational conditions in ISO 5 classified areas (biological safety cabinet and laminar airflow workbench). Smoke studies from June 2023 did not demonstrate first air movement around equipment, supplies, or operator manipulations. A technician was observed blocking first air and not completing production activities during the production of Alprostadil/Papaverine HCl/Phentolamine Mesylate (Tri-Mix) lot 080920203@L.
2. **Facility Design Flaws:** The facility design allowed lesser quality air into higher quality classified areas. A shared vent between the non-hazardous (ISO 8) and hazardous (ISO 7) drug preparation rooms increased the possibility of cross-contamination, with air potentially flowing from the ISO 8 area into the ISO 7 area and being exhausted through the hood used for hazardous drug production. There was no continuous differential pressure monitoring or real-time alarm in these clean
ID · 5483a6f8-bbdd-4aca-a063-a239eb3153e6
Full citation text and observation details available on the Dashboard.